

### IRB approval status

Ethical approval was granted by the Research Ethics Board at Sunnybrook Health Sciences Centre (287-2010) and Women's College Hospital (2010-0041-E).

### Funding sources

None.

### Conflict of interest

Dr. Vender has been a speaker, consultant, advisory board member and investigator for AbbVie, Actelion, Amgen, Astellas, Celgene, Dermira, Eli Lilly, Galderma, Janssen Ortho, Leo, Merck, Novartis, Pfizer, Regeneron and Takeda. Dr. Prajapati has been an investigator for AbbVie, Amgen, Arcutis, Asana, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Concert, Dermira, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, UCB and Valeant; and consultant, advisor and/or speaker for AbbVie, Actelion, Amgen, Aralez, Aspen, Bausch Health, Boehringer Ingelheim, Celgene, CIPHER, Eli Lilly, Galderma, GlaxoSmithKline, HomeoCan, Janssen, LEO Pharma, L'Oreal, Medexus, Novartis, Pediapharm, Pfizer, Sanofi Genzyme, Sun Pharma, Tribute, UCB and Valeant. Dr. Yeung has been a speaker, consultant and investigator for AbbVie, Allergan, Amgen, Arcutis, Astellas, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Centocor, Coherus, Dermavant, Dermira, Forward, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa, Leo Pharma, Lilly, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi Genzyme, Sun Pharma, Takeda, UCB and Xenon. Dr. Georgakopoulos and Dr. Mufti have no conflicts of interest to disclose.

J.R. Georgakopoulos,<sup>1</sup>  A. Mufti,<sup>1</sup> R. Vender,<sup>2,3</sup>   
V.H. Prajapati,<sup>4,5,6,7,8,9</sup> J. Yeung<sup>1,10,11,12,\*</sup>

<sup>1</sup>Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada, <sup>2</sup>Department of Dermatology, McMaster University, Hamilton, ON, Canada, <sup>3</sup>Dermatrics Research Inc. & Venderm Innovations in Psoriasis, Hamilton, ON, Canada, <sup>4</sup>Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, <sup>5</sup>Division of Community Pediatrics, Department of Pediatrics, University of Calgary, Calgary, AB, Canada, <sup>6</sup>Division of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, AB, Canada, <sup>7</sup>Dermatology Research Institute, Calgary, AB, Canada, <sup>8</sup>Skin Health & Wellness Centre, Calgary, AB, Canada, <sup>9</sup>Probiy Medical Research Inc, Calgary, AB, Canada, <sup>10</sup>Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>11</sup>Women's College Hospital, Toronto, ON, Canada, <sup>12</sup>Probiy Medical Research Inc, Waterloo, ON, Canada

\*Correspondence: J. Yeung, E-mail: jensen.yeung@utoronto.ca

### References

- 1 Menter A, Strober BE, Kaplan DH *et al*. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol* 2019; **80**(4): 1029–1072.

- 2 Fahmy DH, El-Amawy HS, El-Samony MA *et al*. COVID-19 and dermatology: a comprehensive guide for dermatologists. *J Eur Acad Dermatol Venereol* 2020; **34**(7): 1388–1394.
- 3 Beecker J, Papp KA, Dutz J *et al*. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. *J Eur Acad Dermatol Venereol* 2021; **35**(4): 797–806.
- 4 Gondo GC, Bell SJ, Slayden J, Ullmann G, Blauvelt A. Concerns and perceptions of patients with psoriatic disease during the COVID-19 pandemic: results from a two-wave survey by the National Psoriasis Foundation. *J Eur Acad Dermatol Venereol* 2021; **35**: e354–e355.
- 5 Georgakopoulos JR, Mufti A, Vender R, Yeung J. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study. *J Am Acad Dermatol* 2020; **83**(4): 1212–1214.
- 6 Williamson EJ, Walker AJ, Bhaskaran K *et al*. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* 2020; **584**(7821): 430–436.
- 7 Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. *Dermatol Ther* 2020; **33**(5): e13475.


DOI: 10.1111/jdv.17279

## Penile ischaemia secondary to COVID-19: why should the dermatologist be concerned?

Editor,

Coronavirus disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with an increased risk of vasculitis and thrombotic vasculopathy. Dermatologically, this can translate to severe cutaneous manifestations, such as retiform purpura and acral ischaemia.<sup>1</sup> But whether these eruptions are specific to SARS-CoV-2 infection is yet to be determined.<sup>2,3</sup> An in-depth understanding and an elaborate characterization of these skin findings are therefore needed, as they can provide more insight into the pathophysiology of this disease and define the role that dermatologists can play amid this pandemic.

To this extent, we herein report the case of a 58-year-old man with a history of type 2 diabetes, hypertension and terminal chronic kidney disease undergoing haemodialysis, presenting to the emergency department for acute penile pain. On physical examination, a retracted penis with phimosis and glans discoloration was noted (Fig. 1). A penile Doppler ultrasound confirmed the diagnosis of penile ischaemia. On further questioning, the patient reported the progressive appearance of ischaemic changes and necrotic lesions on the fingers (Fig. 2a), heels (Fig. 2b) and toes (Fig. 2c) compatible with acral pernio-sis; the advent of these skin findings preceded the chief complaint in a couple of days. A real-time reverse-transcription



**Figure 1** Phimosis and ischaemia of the glans penis, both clinical signs of penile ischaemia, are observed before (a) and after (b) posthectomy.

polymerase chain reaction test for SARS-CoV-2, performed from a nasopharyngeal swab, yielded negative results; however, the patient admits of having been in contact with a confirmed COVID-19-infected person. This, combined with ground-glass opacities found on the patient's thoracic CT scan, was in favour of a recent COVID-19 infection, albeit the PCR's negative results. A posthectomy that involved the debridement of the ischaemic tissue was performed. Pathological assessment of the penile surgical specimen showed necrotic tissue, as well as microvascular thrombosis and leucocytic infiltration of the vascular walls. In the hypothesis of antiphospholipid antibodies syndrome, serologic testing was done, and it did not show any antibodies. Due to the lack of consensus on the treatment of perniosis, antiplatelet therapy and oral analgesics were administered.<sup>4</sup> Topical treatments were not given.

This is to the best of our knowledge the first reported case of penile ischaemia associated with COVID-19 infection. The combined cutaneous and penile presentation can give us more evidence of the physiopathology of this disease. First, it underlines the severe hypercoagulability and thrombotic tendency observed in COVID-19, since penile ischaemia is a rare complication owing to its rich collateral vascularization.<sup>5</sup> This clinical scenario is similar to the one reported by del Giudice *et al.*<sup>6</sup> in your journal, further supporting the author's assumption that acro-ischaemic lesions could be the consequence of the malignant synergy of the vasculitis and severe coagulopathy

observed in COVID-19.<sup>7</sup> Secondly, the perniosis-like lesions appeared distant to the initial phase of SARS-CoV-2 infection; we might hypothecate that our findings represent a late and indirect manifestation of this disease. Finally, our patient had undetectable antiphospholipid antibodies, which counter the proposition advanced by Zhang *et al.* that these antibodies are the source of coagulopathies in COVID-19.<sup>8</sup>

On another note, this case highlights the considerable role dermatologists have in this pandemic. Our patient's acral necrosis preceded penile ischaemia, making skin necrosis the first reflection of the ongoing thromboinflammatory process due to COVID-19. And because of the prevalence of dermatological manifestations in infected patients (reported as high as 20.4%<sup>9</sup>), dermatologists must be actively involved in patients' care and follow-up during this outbreak. With the current need for self-isolation and social distancing, teledermatology should therefore come to the fore to provide patients ongoing access to dermatologic care, including those with confirmed or suspected of having COVID-19.<sup>10</sup>

#### Funding sources

None.

#### Consent

The patients in this manuscript have given written informed consent to publication of their case details.



**Figure 2** Acro-ischæmic lesions are seen on the fingers (a), heels (b) and toes (c).

### Conflict of Interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

P. Sarkis,<sup>1</sup> J. Sarkis,<sup>2\*</sup>  M. Alkassis,<sup>2</sup>  J. Assaf,<sup>3</sup>   
K. El Gharib<sup>4</sup> 

<sup>1</sup>Department of Urology, Saint Joseph Hospital, Beirut, Lebanon,

<sup>2</sup>Department of Urology, Hotel-Dieu de France Hospital, Beirut, Lebanon,

<sup>3</sup>Department of Dermatology, Hôtel-Dieu de France Hospital, Beirut, Lebanon, <sup>4</sup>Saint Joseph University, Beirut, Lebanon

\*Correspondence: J. Sarkis. E-mail: juliensarkis@live.com

likely consequence of both vasculitis and coagulopathy. *J Eur Acad Dermatol Venereol* 2020; **34**: e679–e680. <https://doi.org/10.1111/jdv.16763>.

- 7 de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P *et al*. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? *J Eur Acad Dermatol Venereol* 2020; **34**(10): e566–e568.s
- 8 Zhang Y, Xiao M, Zhang S *et al*. Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med* 2020; **382**: e38.
- 9 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol JEADV* 2020; **34**: e212–e213.
- 10 Moscarella E, Pasquali P, Cinotti E, Tognetti L, Argenziano G, Rubegni P. A survey on tele dermatology use and doctors' perception in times of COVID-19. *J Eur Acad Dermatol Venereol* 2020; **34**: e772–e773.

DOI: 10.1111/jdv.17287

### References

- 1 Freeman EE, McMahon DE, Lipoff JB *et al*. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. *J Am Acad Dermatol* 2020; **83**: 1118–1129.
- 2 Matar S, Oulès B, Sohler P *et al*. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. *J Eur Acad Dermatol Venereol* 2020; **34**: e686–e689.
- 3 Suarez-Valle A, Fernandez-Nieto D, Diaz-Guimaraens B, Santas MD, Carretero I, Garcia BP. Acro-ischæmia in hospitalized COVID-19 patients. *J Eur Acad Dermatol Venereol* 2020; **34**: e455–e457.
- 4 Ladha MA, Luca N, Constantinescu C, Naert K, Ramien ML. Approach to Chilblains during the COVID-19 pandemic. *J Cutan Med Surg* 2020; **24**: 504–517.
- 5 Simonsen U, García-Sacristán A, Prieto D. Penile arteries and erection. *J Vasc Res* 2002; **39**: 283–303.
- 6 Giudice PD, Boudoumi D, Guen BL *et al*. Catastrophic acute bilateral lower limbs necrosis associated with COVID-19 as a

## Pityriasis rosea, COVID-19 and vaccination: new keys to understand an old acquaintance

Dear Editor,

Lately, we have witnessed sporadic reports of Pityriasis rosea (PR) and PR-like eruptions associated with SARS-CoV-2.<sup>1</sup> Such relationship has raised debate on the possible aetiopathogenic mechanism underlying this exanthematous disease. Our aim is to reinforce the link between PR and coronaviruses based on our finding of two cases following COVID-19 vaccination – the first